Our study demonstrated that the down-regulation of MYL3 expression can effectively alleviate pathological cardiac hypertrophy, thereby offering new insights into the role of MYL3 in cardiac hypertrophy. The gene discussed is MYL3; the disease is cardiac hypertrophy.